抗惊厥药市场：按药物类别、给药途径、适应症、分销渠道、地区 - 规模、份额、前景和机会分析，2022-2030 年

抗惊厥药是一类用于治疗癫痫发作的药物。 由于许多抗惊厥药倾向于充当情绪稳定剂，因此它们也越来越多地用于治疗神经性疼痛、双相情感障碍和边缘型人格障碍。 加巴喷丁、卡马西平和丙戊酸等抗惊厥药通过阻断细胞神经元水平的钠（丙戊酸和加巴喷丁类）或钙（卡马西平和奥卡西平）通道来缓解慢性疼痛。据信 这抑制了自发的电活动并恢復了超敏伤害性神经元去极化的正常阈值，而不影响正常的神经传导。

这些药物对患有神经性疼痛和情绪障碍的患者最有效。 抗惊厥药分为第一代（经典）和第二代药物。 第二代抗惊厥药通常比传统抗惊厥药耐受性更好，治疗窗更广。 药物的选择取决于癫痫发作的类型。 局灶性发作的一线药物是拉莫三秦或左乙拉西坦，丙戊酸盐用于全身性发作。 所有抗惊厥药都有剂量依赖性中枢神经系统副作用（如嗜睡和噁心），但选择性药物有其他副作用（如苯妥英引起的牙龈增生）。

市场动态

预计癫痫病患病率的增加将推动预测期内的市场增长。 例如，根据世界卫生组织的数据，截至 2022 年 2 月，癫痫将成为全球最常见的神经系统疾病之一，影响约 5000 万人。 近 80% 的癫痫患者生活在低收入和中等收入国家。 根据同一份文件，估计如果诊断和治疗得当，多达 70% 的癫痫患者可以无癫痫发作地生活。

这项研究的主要特点

• 本报告对以 2021 年为基准年的预测期 (2022-2030) 的全球抗惊厥药市场、市场规模和復合年增长率 (CAGR%) 进行了深入分析。
• 解释了不同细分市场的潜在创收机会，并描述了针对该市场的有吸引力的投资建议矩阵。
• 它还提供了有关市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景、主要参与者采用的竞争战略等方面的重要见解。
• 根据公司亮点、按类型划分的产品组合、主要亮点、财务业绩和市场战略等参数，介绍全球抗惊厥药市场主要参与者的概况。
• 本研究涵盖的主要公司包括 Novartis AG、GSK plc.、Johnson & Johnson、Teva Pharmaceutical Industries Ltd.、Pfizer, Inc.、Zogenix、Dr. Reddy's Laboratories Ltd.、Alkem Labs、SK BIOPHARMACEUTICALS、Eisai Co. , Ltd, Angelini S.p.a., Sun Pharmaceutical Industries Ltd., UCB S.A., Unichem Laboratories, Jazz Pharmaceuticals, Inc., Neuropathix, Inc., Xenon Pharmaceuticals, Inc., SK Life Science, Inc., Sumitomo Pharma Co., Ltd, and博士伦健康公司
• 这份报告中的见解将使企业营销人员和高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。.
• 《全球抗惊厥药市场》报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
• 利益相关者可以通过用于分析全球抗惊厥药市场的各种战略矩阵来促进决策制定。

内容

第 1 章目的和先决条件

• 调查目的
• 先决条件
• 缩写说明

第二章市场展望

• 报告内容
  • 市场定义和范围
• 执行摘要
  • 市场概况：按药物类别
  • 按给药途径划分的市场概况
  • 市场概况：按指示
  • 市场概况：按分销渠道
  • 市场概况：按地区
  • 市场机会地图

第 3 章抗惊厥药的全球市场洞察

• 司机
• 约束因素
• 市场机会
• 影响分析
• 管道分析
• 害虫分析
• 主要发展状况
• 监管情景
• 合併/收购场景
• 定价分析
• 品牌映射

第 4 章全球抗惊厥药市场 - 冠状病毒 (COVID-19) 大流行的影响

• COVID-19 的流行病学特征
• 对供需的影响
• 对临床试验的影响

第 5 章全球抗惊厥药市场：按药物类别，2017-2030

• 巴比妥类药物
• 苯二氮卓类
• 芳香烯丙醇
• 甲□胺
• 三秦
• AMPA 受体拮抗剂
• 氨基甲酸酯
• 乙内□尿
• 脂肪酸衍生物
• GABA 类似物
• 丙丙□胺
• 其他（丙酸盐、噁唑烷二酮等）

第 6 章全球抗惊厥药市场：按给药途径，2017-2030

• 肠内管理
• 父母代理人

第 7 章全球抗惊厥药市场：按适应症分类，2017-2030

• 癫痫症
• 神经性疼痛
• 焦虑症
• 纤维肌痛
• 躁郁症
• 其他（边缘性人格障碍等）

第 8 章全球抗惊厥药市场：按分销渠道，2017-2030

• 医院药房
• 零售药房
• 在线药店

第 9 章全球抗惊厥药市场：地区，2017-2030

• 北美
• 美国
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地区
• 欧洲
• 德国
• 英国
• 法国
• 意大利
• 西班牙
• 俄罗斯
• 其他欧洲地区
• 亚太地区
• 中国
• 印度
• 日本
• 澳大利亚
• 韩国
• 东盟
• 其他亚太地区
• 中东
• 海湾合作委员会
• 以色列
• 其他中东地区
• 非洲
• 南非
• 中非
• 北非

第十章公司简介

• 诺华公司
  • 公司亮点
  • 产品组合
  • 主要亮点
  • 财务业绩
  • 市场策略
• GSK plc.
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.
• Pfizer, Inc.
• Zogenix
• DR. Reddy's Laboratories Ltd.
• Alkem Labs
• SK BIOPHARMACEUTICALS
• Eisai Co., Ltd
• Angelini S.p.a.
• Sun Pharmaceutical Industries Ltd.
• UCB S.A.
• Unichem Laboratories
• Jazz Pharmaceuticals, Inc.
• Neuropathix, Inc.
• Xenon Pharmaceuticals, Inc.
• SK Life Science, Inc.
• Sumitomo Pharma Co., Ltd
• Bausch Health Companies Inc.

第 11 章章节

• 调查方法
• 关于出版商

Anticonvulsants are a broad class of drugs used to treat epileptic seizures. Since many anticonvulsants tend to operate as mood stabilizers, they are also being used more frequently to treat neuropathic pain, bipolar disorder, and borderline personality disorder. Anticonvulsants, including gabapentin, carbamazepine, and valproic acid, are believed to alleviate chronic pain by obstructing sodium (valproate and the gabapentanoids) or calcium (carbamazepine and Oxcarbazepine) channels at the cellular neuronal level. This suppresses spontaneous electrical activity and restores the normal threshold to depolarization of hypersensitive nociceptive neurons without affecting normal nerve conduction.

Patients with neuropathic pain and mood disorders benefit most from these drugs. Anticonvulsant drugs are classified as either first-generation (classic) agents or second-generation agents. Second-generation anticonvulsants are usually better tolerated and have a broader therapeutic range than classic anticonvulsant drugs. The choice of drug is guided by the type of seizure. First-line treatment for focal seizures includes lamotrigine or levetiracetam, while valproate is used for generalized seizures. While all anticonvulsants have dose-dependent side effects on the central nervous system (e.g., somnolence, nausea), select agents also have other side effects (e.g., gingival hyperplasia caused by phenytoin).

Market Dynamics

Increasing prevalence of epilepsy is expected to propel the market growth over the forecast period. For instance, according to the World Health Organization, in February 2022, epilepsy is one of the most common neurological diseases globally, which affects around 50 million people. Nearly 80% of people with epilepsy live in low- and middle-income countries. According to the same source, it is estimated that up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated.

Key features of the study:

• This report provides an in-depth analysis of the global anticonvulsant drugs market, market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global anticonvulsant drugs market based on the following parameters - company highlights, types portfolio, key highlights, financial performance, and market strategies
• Key companies covered as a part of this study include Novartis AG, GSK plc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy's Laboratories Ltd., Alkem Labs, SK BIOPHARMACEUTICALS, Eisai Co., Ltd, Angelini S.p.a., Sun Pharmaceutical Industries Ltd., UCB S.A., Unichem Laboratories, Jazz Pharmaceuticals, Inc., Neuropathix, Inc., Xenon Pharmaceuticals, Inc., SK Life Science, Inc., Sumitomo Pharma Co., Ltd, and Bausch Health Companies Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global anticonvulsant drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anticonvulsant drugs market

Detailed Segmentation:

• Global Anticonvulsant Drugs Market, By Drug Class:
  • Barbiturates
  • Benzodiazepines
  • Aromatic allylic alcohols
  • Carboxamides
  • Triazine
  • AMPA receptor antagonists
  • Carbamate
  • Hydantoin
  • Fatty Acid Derivative
  • GABA analogs
  • Valproylamides
  • Others (Propionates, Oxazolidinediones, etc.)
• Global Anticonvulsant Drugs Market, By Route of Administration:
  • Enteral
  • Parenteral
• Global Anticonvulsant Drugs Market, By Indication:
  • Epilepsy
  • Neuropathic pain
  • Anxiety
  • Fibromyalgia
  • Bipolar Disorder
  • Others (Borderline personality disorder, etc.)
• Global Anticonvulsant Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Anticonvulsant Drugs Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country/Region
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Novartis AG
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • GSK plc.
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • Zogenix
  • Dr. Reddy's Laboratories Ltd.
  • Alkem Labs
  • SK BIOPHARMACEUTICALS
  • Eisai Co., Ltd
  • Angelini S.p.a.
  • Sun Pharmaceutical Industries Ltd.
  • UCB S.A.
  • Unichem Laboratories
  • Jazz Pharmaceuticals, Inc.
  • Neuropathix, Inc.
  • Xenon Pharmaceuticals, Inc.
  • SK Life Science, Inc.
  • Sumitomo Pharma Co., Ltd
  • Bausch Health Companies Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Indication
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
  • Market Opportunity Map

3. Global Anticonvulsant Drugs Market Insights

• Drivers
• Restraints
• Opportunity
• Impact Analysis
• Pipeline Analysis
• PEST Analysis
• Key Developments
• Regulatory Scenario
• Merger & Acquisition Scenario
• Pricing Analysis
• Brand Mapping

4. Global Anticonvulsant Drugs Market- Impact of Coronavirus (Covid-19) Pandemic

• COVID-19 Epidemiology
• Impact On Supply And Demand
• Impact on Clinical Trials

5. Global Anticonvulsant Drugs Market, By Drug Class, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Barbiturates
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Benzodiazepines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Aromatic allylic alcohols
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Carboxamides
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Triazine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• AMPA receptor antagonists
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Carbamate
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Hydantoin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Fatty Acid Derivative
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• GABA analogs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Valproylamides
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Others (Propionates, Oxazolidinediones, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

6. Global Anticonvulsant Drugs Market, By Route of Administration, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Enteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

7. Global Anticonvulsant Drugs Market, By Indication, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Epilepsy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Neuropathic pain
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Anxiety
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Fibromyalgia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Bipolar Disorder
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Others (Borderline personality disorder, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

8. Global Anticonvulsant Drugs Market, By Distribution Channel, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

9. Global Anticonvulsant Drugs Market, By Region, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Region at Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country/Region, 2017-2030, (US$ Million)
• South Africa
• Central Africa
• North Africa

10. Company Profiles

• Novartis AG*
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• GSK plc.
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.
• Pfizer, Inc.
• Zogenix
• DR. Reddy's Laboratories Ltd.
• Alkem Labs
• SK BIOPHARMACEUTICALS
• Eisai Co., Ltd
• Angelini S.p.a.
• Sun Pharmaceutical Industries Ltd.
• UCB S.A.
• Unichem Laboratories
• Jazz Pharmaceuticals, Inc.
• Neuropathix, Inc.
• Xenon Pharmaceuticals, Inc.
• SK Life Science, Inc.
• Sumitomo Pharma Co., Ltd
• Bausch Health Companies Inc.

11. Section

• Research Methodology
• About us